Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Public Health and Surveillance

Date Submitted: Feb 15, 2022
Date Accepted: Apr 27, 2022
Date Submitted to PubMed: Apr 29, 2022

The final, peer-reviewed published version of this preprint can be found here:

COVID-19 Surveillance in the Biobank at the Colorado Center for Personalized Medicine: Observational Study

Johnson RK, Marker KM, Mayer D, Shortt J, Kao D, Barnes KC, Lowery JT, Gignoux CR

COVID-19 Surveillance in the Biobank at the Colorado Center for Personalized Medicine: Observational Study

JMIR Public Health Surveill 2022;8(6):e37327

DOI: 10.2196/37327

PMID: 35486493

PMCID: 9196874

COVID-19 Surveillance in the Biobank at the Colorado Center for Personalized Medicine: Observational Study

  • Randi K. Johnson; 
  • Katie M. Marker; 
  • David Mayer; 
  • Jonathan Shortt; 
  • David Kao; 
  • Kathleen C. Barnes; 
  • Jan T. Lowery; 
  • Christopher R. Gignoux

ABSTRACT

Background:

Characterizing the experience and impact of the COVID-19 pandemic among various populations remains challenging due to the limitations inherent in common data sources such as the electronic health record (EHR) or convenience sample surveys.

Objective:

To describe testing behaviors, symptoms, impact, vaccination status and case ascertainment during the COVID-19 pandemic using integrated data sources.

Methods:

In summer 2020 and 2021, we surveyed participants enrolled in the Biobank at the Colorado Center for Personalized Medicine (CCPM, N = 180,599) about their experience with COVID-19. Prevalence of testing, symptoms, and the impacts of COVID-19 on employment, family life, and physical and mental health were calculated overall and by demographic categories. Using the Electronic Health Record (EHR), we compared COVID-19 case ascertainment and characteristics in the EHR versus the survey.

Results:

Of the 25,063 survey respondents (13.9%), 42.5% had been tested for COVID-19 and of those, 12.8% tested positive. Nearly half of those tested had symptoms and/or had been exposed to someone who was infected. Young adults (18-29 years) and Hispanics were more likely to have positive tests compared to older adults and persons of other racial/ethnic groups. Mental health (54.6%) and family life (48.8%) were most negatively affected by the pandemic and more so among younger groups and women; negative impacts on employment were more commonly reported among Black respondents. After integration with EHR data up to the time of the survey completion, 4.0% of survey respondents (n=1,006) had discordant COVID-19 case status between the EHR and the survey. Using all longitudinal EHR and survey data, we identified 11,472 COVID-positive cases among Biobank participants (6.4%). In comparison to COVID-19 cases identified through the survey, EHR-identified cases were younger and more likely to be Hispanic.

Conclusions:

Integrated data assets such as the Biobank at the CCPM are key resources for population health monitoring in response to public health emergencies, such as the COVID-19 pandemic.


 Citation

Please cite as:

Johnson RK, Marker KM, Mayer D, Shortt J, Kao D, Barnes KC, Lowery JT, Gignoux CR

COVID-19 Surveillance in the Biobank at the Colorado Center for Personalized Medicine: Observational Study

JMIR Public Health Surveill 2022;8(6):e37327

DOI: 10.2196/37327

PMID: 35486493

PMCID: 9196874

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.